Feasibilty and Acceptability of Amani, a Virtual Reality Application for Adults With Sickle Cell Disease
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Feasibility
研究概览
简要总结
Adults with sickle cell disease (SCD) experience severe pain, emotional distress, and social isolation that diminish their quality of life. This project will test Amani, a novel virtual reality supportive care intervention designed to improve coping skills and strengthen peer support. If feasible and acceptable, Amani offers an accessible digital supportive care intervention to improve psychological well-being and quality of life among individuals living with SCD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (≥ 18 years) who are diagnosed with sickle cell disease
- •Primarily followed at the Massachusetts General Hospital (MGH) Sickle Cell Disease Center
- •Have ability to comprehend and speak English given Amani is currently only available in English.
排除标准
- •Have severe psychiatric (psychotic disorder, bipolar disorder) or cognitive impairment which the treating hematologist believes would preclude ability to participate in the clinical trial
研究组 & 干预措施
Amani
Patients enrolled will receive Amani, which is a virtual reality intervention administered over 5 weeks. Amani is a virtual reality based supportive care intervention specifically tailored for adults with SCD. Amani integrates mindfulness-based pain management exercises, psychoeducational modules to build adaptive coping strategies, and facilitated group sessions in virtual reality to reduce isolation and foster peer support
干预措施: Amani (Behavioral)
结局指标
主要结局
Feasibility
时间窗: From enrollment to end of treatment (6 weeks)
Amani will be feasible based on proportion of eligible patients enrolled (≥50% of eligible patients enroll), application educational module completion (≥60% of enrolled participants complete the educational modules) and group intervention attendance (≥60% of Amani group sessions).
次要结局
- Acceptability(From enrollment to end of treatment (6 weeks))
研究者
Richard Andrew Newcomb, MD
Attending Physician, Assistant Professor of Medicine
Massachusetts General Hospital